ClinicalTrials.gov
ClinicalTrials.gov Menu

Extent of Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01149161
Recruitment Status : Recruiting
First Posted : June 23, 2010
Last Update Posted : April 21, 2016
Sponsor:
Information provided by (Responsible Party):
Jee soo Kim, Samsung Medical Center

Brief Summary:
Occult lymph node metastasis is common in micro papillary thyroid cancer. However, the role of lymph node dissection in the treatment of microPTC remains controversial. The investigators want to investigate the usefulness routine central dissection and sentinel lymph node biopsy in prognosis of micro PTC. This is a prospective randomized control study. The investigators started this study from May of 2009 and this study will be continued until Dec. 2011.

Condition or disease Intervention/treatment Phase
Carcinoma Procedure: Routine central neck dissection Phase 2 Phase 3

Detailed Description:
The investigators will assign all patients to three groups; no dissection group (Group I), sentinel lymph node biopsy only group (Group II) and routine central neck dissection group (Group III). At first, to know the necessity of routine central neck node dissection for micro PTC,the investigators will compare the result of group I and group III. Additionally, the investigators can analyze the usefulness of sentinel lymph node biopsy for substitution of routine central neck node dissection for micro PTC.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 2000 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Care Provider)
Primary Purpose: Treatment
Official Title: Sentinel Lymph Node Biopsy in the Thyroid Carcinoma; Randomized, Prospective Study
Study Start Date : May 2009
Estimated Primary Completion Date : December 2017
Estimated Study Completion Date : December 2020

Resource links provided by the National Library of Medicine

Drug Information available for: Thyroid
U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: C group
Routine central neck dissection
Procedure: Routine central neck dissection
Level VI neck node dissection during thyroid operation
No Intervention: N group
No central neck node dissection



Primary Outcome Measures :
  1. Is routine neck node dissection necessary in micro PTC? [ Time Frame: Until 5 year follow-up. (Dec. 2016) ]

    To see the necessity of routine neck node dissection in micro PTC, we will compare the recurrence rate and other complication (e.g. hoarseness and hypocalcemia) between group I(no dissection) and group III(routine dissection) after completion of study(after 5 year f/u).

    To check the safety of this study, our result will be checked by korea institutional reveiw board every one year.



Secondary Outcome Measures :
  1. The efficacy of sentinel lymph node biopsy in micro PTC [ Time Frame: Until 5 year follow-up. (Dec. 2016) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • papillary carcinoma of thyroid (less than 4cm)
  • no evidence of lymph node metastasis in preoperative work-up result
  • the patients who accept this study

Exclusion Criteria:

  • large thyroid cancer( > 4cm)
  • morbid
  • anticoagulation agent usage
  • endoscopic or robotic thyroid operation
  • evidence of lymph node metastasis or extrathyroidal extension in preoperative US and CT scan

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01149161


Contacts
Contact: Jee Soo Kim, M.D., Ph.D. 82-2-3410-3479 js0507.kim@samsung.com

Locations
Korea, Republic of
Samsung Medical Center Recruiting
Seoul, Korea, Republic of, 135-710
Contact: Jee Soo Kim, M.D., Ph.D.    82-2-3410-3479      
Sponsors and Collaborators
Samsung Medical Center
Investigators
Study Chair: Jee Soo Kim, M.D., Ph.D. Samsung Medical Center

Responsible Party: Jee soo Kim, Associate professor, Samsung Medical Center
ClinicalTrials.gov Identifier: NCT01149161     History of Changes
Other Study ID Numbers: 2009-02-017
First Posted: June 23, 2010    Key Record Dates
Last Update Posted: April 21, 2016
Last Verified: April 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Jee soo Kim, Samsung Medical Center:
neck dissection
sentinel lymph node
Carcinoma
Papillary
thyroid
dissection

Additional relevant MeSH terms:
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms